GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.

Al-Ali D, El Hajj N

Open source

DOI
10.1016/j.exger.2026.113325
Published
2026 Sep 14
Container
Experimental gerontology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.exger.2026.113325,
  title = {GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.},
  author = {Al-Ali D and El Hajj N},
  year = {2026},
  journal = {Experimental gerontology},
  doi = {10.1016/j.exger.2026.113325},
  url = {https://doi.org/10.1016/j.exger.2026.113325}
}

RIS

TY  - JOUR
TI  - GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.
AU  - Al-Ali D
AU  - El Hajj N
PY  - 2026
JO  - Experimental gerontology
DO  - 10.1016/j.exger.2026.113325
UR  - https://doi.org/10.1016/j.exger.2026.113325
ER  - 

APA

D, A., & N, E. H. (2026). GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.. Experimental gerontology. https://doi.org/10.1016/j.exger.2026.113325

Source records